Genpact launches AI solution for drug safety automation

Genpact’s new PVAI solution promises to transform drug safety data management and reporting

Genpact, a services firm focused on delivering digital transformation for clients, is investing in digital technologies that are transforming industries.

Genpact’s Pharmacovigilance Artificial Intelligence (PVAI) will be the life sciences industry’s first fully integrated, end to end adverse event (AE) processing solution.

Leveraging intelligent automation, to not only dramatically reduce the effort of processing adverse events, but also to enable an AI driven level of real time predictive analytics and actionable insight, which was previously not possible.

As life sciences companies face escalating AE volumes for products and increasing pressure to improve quality and compliance while reducing costs, they are looking for breakthrough solutions to help transform pharmacovigilance operations.

Genpact’s PVAI solution brings together and integrates optical character recognition, robotic process automation, natural language processing and machine learning technologies.

To automatically extract and code AE data from unstructured and semi-structured source documents — eliminating manual workflow, saving pharmaceutical companies significant time and resources, and helping to establish a scalable PV operating model.

Most importantly, the solution continuously builds predictive insights as more and more AE goes through it over time.

Balkrishan Kalra, Senior Vice President and Business Leader, Consumer Goods, Retail, Life Sciences and Healthcare at Genpact, said: ”Industry leaders have stated that the current manually intensive approach to AE processing is simply not sustainable and needs an innovative approach.

“Through robust pilot testing with clients, our new PVAI solution has proven that the vast majority of case processing can be successfully automated in a fraction of the time and cost. We continue to invest in PVAI and are excited to bring this holistic, unique and market-leading, AI-driven digital proposition to the industry."

As part of its investments in PVAI, Genpact recently acquired the assets and team of November Research Group (NRG), a Berkeley, California based provider of product vigilance software.

The transaction added NRG’s domain expertise and fully featured pharmacovigilance Software-as-a-Service, contributing to PVAI’s pioneering approach to automating drug safety operations in the life sciences industry.

Brad Gallien, Vice President at November Research Group, said: ”The November Research Group team is very excited to be part of the Genpact PVAI team and combining our deep domain expertise and our PV solutions with their AE data extraction engine, analytics, and innovative AI approach to provide a truly game-changing PV solution. Together, we are creating a new paradigm for drug safety."

Companies